Effectiveness and safety in Crohn's disease patients who were treated with CT-P13

被引：0
|
作者：
Choe, Y. H. [1 ]
Lee, S. -H. [2 ]
Park, D. I. [3 ]
Lee, J. H. [4 ]
Kim, H. J. [5 ]
Kim, Y. -H. [6 ]
Choi, C. H. [7 ]
Eun, C. S. [8 ]
Lee, S. J. [9 ]
Lee, S. [9 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Dept Pediat, Samsung Med Ctr, Seoul, South Korea
[2] Esoo Hosp, Digest Endoscop Ctr, Cheonan Si, South Korea
[3] Kangbuk Samsung Hosp, Dept Internal Med, Seoul, South Korea
[4] Seoul Song Do Colorectal Hosp, Dept Internal Med, Seoul, South Korea
[5] Kyung Hee Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[6] Sungkyunkwan Univ, Sch Med, Dept Internal Med, Samsung Med Ctr, Seoul, South Korea
[7] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[8] Hanyang Univ, Coll Med, Dept Internal Med, Guri Hosp, Guri, South Korea
[9] CELLTRION Inc, Incheon, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2017年 / 11卷
关键词：
INFLIXIMAB;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P500
引用
收藏
页码：S333 / S333
页数：1
相关论文
共 50 条
  • [1] EFFECTIVENESS AND SAFETY IN CROHN'S DISEASE PATIENTS WHO WERE TREATED WITH CT-P13
    Choe, Yon Ho
    Lee, Suck-Ho
    Park, Dongil
    Lee, Ji Hyun
    Kim, Hyo-Jong
    Kim, Young Ho
    Choi, Chang Hwan
    Eun, Chang Soo
    Lee, Sang Joon
    Lee, SunHee
    GASTROENTEROLOGY, 2017, 152 (05) : S406 - S406
  • [2] Infliximab biosimilar CT-P13 in Crohn's disease
    Gecse, Krisztina B.
    D'Haens, Geert R.
    LANCET, 2019, 393 (10182): : 1671 - 1672
  • [3] Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis
    Gheorghe, Cristian
    Svoboda, Pavel
    Mateescu, Bogdan
    JOURNAL OF DRUG ASSESSMENT, 2019, 8 (01) : 129 - 134
  • [4] Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease
    Chaparro, M.
    Garre, A.
    Guerra Veloz, M. F.
    Vazquez Moron, J. M.
    De Castro, M. L.
    Leo, E.
    Rodriguez, E.
    Carbajo, A. Y.
    Riestra, S.
    Jimenez, I.
    Calvet, X.
    Bujanda, L.
    Rivero, M.
    Gomollon, F.
    Benitez, J. M.
    Bermejo, F.
    Alcaide, N.
    Gutierrez, A.
    Manosa, M.
    Iborra, M.
    Lorente, R.
    Rojas-Feria, M.
    Barreiro-de Acosta, M.
    Kolle, L.
    Van Domselaar, M.
    Amo, V.
    Arguelles, F.
    Ramirez, E.
    Morell, A.
    Bernardo, D.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 (11): : 1380 - 1386
  • [5] Effectiveness and safety of CT-P13 under routine care in paediatric patients with inflammatory bowel disease
    Choe, Y. H.
    Yang, H. R.
    Moon, J. S.
    Ryoo, E.
    Kim, S.
    Lee, J. H.
    Kim, H. J.
    Park, J. H.
    Kim, M. J.
    Lee, S. J.
    Lee, S. Y.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S326 - S327
  • [6] EFFECTIVENESS AND SAFETY OF CT-P13 UNDER ROUTINE CARE IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Choe, Yon Ho
    Yang, Hye Ran
    Moon, Jin Soo
    Ryoo, Eell
    Kim, Seung
    Lee, Ji Hyun
    Kim, Hyo-Jong
    Park, Jae Hong
    Kim, Mi Jin
    Lee, Sang Joon
    Lee, Sung Young
    GASTROENTEROLOGY, 2017, 152 (05) : S396 - S396
  • [7] Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure
    Caron, Benedicte
    Fumery, Mathurin
    Netter, Patrick
    Peyrin-Biroulet, Laurent
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 508 - 509
  • [8] Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis
    Kim, Eun Soo
    Kim, Sung Kook
    Park, Dong Il
    Kim, Hyo Jong
    Lee, Yoo Jin
    Koo, Ja Seol
    Kim, Eun Sun
    Yoon, Hyuk
    Lee, Ji Hyun
    Kim, Ji Won
    Shin, Sung Jae
    Kim, Hyung Wook
    Kim, Hyun-Soo
    Park, Young Sook
    Kim, You Sun
    Kim, Tae Oh
    Lee, Jun
    Choi, Chang Hwan
    Han, Dong Soo
    Chun, Jaeyoung
    Kim, Hyun Soo
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2023, 57 (06) : 601 - 609
  • [9] An observational, prospective cohort study to evaluate the long term safety and effectiveness of intravenous CT-P13 (biosimilar of infliximab) in patients with Crohn's Disease or Ulcerative Colitis
    Cheon, J. H.
    Kang, H. W.
    Lee, S. J.
    Kim, S. H.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S378 - S378
  • [10] COST-EFFECTIVENESS OF INFLIXIMAB'S BIOSIMILAR CT-P13 COMPARED TO INNOVATOR INFLIXIMAB FOR THE MANAGEMENT OF CROHN'S DISEASE.
    Beilman, Candace L.
    Ma, Christopher
    McCabe, Christopher
    Fedorak, Richard N.
    Halloran, Brendan P.
    GASTROENTEROLOGY, 2017, 152 (05) : S447 - S447
12345